Developed and marketed treatments for ADHD. Offered therapies for hereditary angioedema. Now — the numbers.
This is an established company with proven profits.
Average growth of 32% a year over the last 4 years. Every year shown ended in profit.
The gap is $19.1B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The net profit margin is 28% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 4 years, sales grew about 32% a year on average.
It pays out $1.06 per share each year — regular cash for whoever holds the stock.
The price action doesn’t yet back an upward turn. Council score: 0/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown, the price history.